Aardvark Therapeutics, Inc.
AARD· Nasdaq
AARDAardvark Therapeutics, Inc.
Filed Nov 13, 2025 · 10-Q · 44 days after period end · 0001193125-25-280260
| Metric | Q3 2025 | Q3 2024 |
|---|---|---|
| Revenue | $0.00 | — |
| Net Income | -$16.32M | -$4.18M |
| EPS Diluted | -$0.75 | -$1.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aardvark Therapeutics, Inc. · CIK 1774857 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end
